Our Integrated Report 2022

Discover how we’re making the impossible possible to improve people's lives everywhere

Meet Naimish Patel

Jamming at home with his daughters, Naimish admits he would have loved to have become a professional musician, but instead he channeled his curiosity into the world of research to unravel the complicated process of chasing the miracles of science to improve people’s lives.

Rethinking the Science of COPD

Chronic obstructive pulmonary disease (COPD) is the third most common cause of death worldwide. Learn how we are working to transform the way COPD is understood and treated in partnership with Regeneron.

Dream Big

Born with a congenital disease that prevented his right forearm and right pectoral muscle from developing, David passionately believes in the importance of dreaming big no matter what challenges you face. What’s his dream? Building a better world, one LEGO® brick at a time.

First quarter 2023 results

Strong Q1 growth driven by Specialty Care, Vaccines and CHC

The Road to Innovation in Hemophilia Treatment

Ekta and her colleagues researched potential treatments to support those living with this rare blood disorder. Their research resulted in a new option that can offer greater flexibility and freedom to many within this community.

Sanofi iDEA-iTECH Awards 2023

Recent award recipients share how winning this award and collaborating with Sanofi researchers has impacted their work.

Sanofi Today

Your Health

May 23, 2023

Why Words Really Matter When It Comes to Multiple Sclerosis

Our latest news

May 25, 2023
Press Release: Annual General Meeting of May 25, 2023 – Frédéric Oudéa new Chairman of the Board of Directors
May 21, 2023
Press Release: Dupixent® (dupilumab) late-breaking Phase 3 COPD results presented at ATS and simultaneously published in the New England Journal of Medicine
May 12, 2023
Press Release: Nirsevimab delivers 83% reduction in RSV infant hospitalizations in a real-world clinical trial setting
May 8, 2023
Media Update: Positive data from two Phase 3 Dupixent® (dupilumab) trials in prurigo nodularis published in Nature Medicine

Explore More

Sanofi X Paris 2024

Igniting the Potential in Everyone

Our Legacy

Our company of today is built on a heritage of turning the impossible into the possible

Our Integrated Report 2021

We chase the miracles of science to improve people’s lives and to transform the practice of medicine

Explore Career Opportunities

You'll be surprised what you can achieve at Sanofi. Discover your future here.